BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET

Company Participants

Irina Koffler – Corporate Participant
Mali Zeevi – Chief Financial Officer
Philip A. Serlin – Chief Executive Officer

Conference Call Participants

John D. Vandermosten – Zacks Investment Research, Inc.
Joseph Pantginis – H.C. Wainwright & Co, LLC, Research Division
Justin Howard Walsh – JonesTrading Institutional Services, LLC, Research Division

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] I would now like to turn over the call to Irina Koffler, Investor Relations Irina, please go ahead.

Irina Koffler

Thank you, operator, and welcome, everyone. Thank you for joining us on our quarterly results conference call. Earlier today, we issued a press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6-K. I’d like to remind you that certain statements we make during the call were forward-looking. Because such statements deal with future events and are subject to many risks and uncertainties. Actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20-F and our quarterly reports on Form 6-K that are filed with the U.S. Securities and Exchange Commission. At this time, it is now my pleasure to turn the call over to Mr. Phil Serlin, Chief Executive Officer of BioLineRx.

Philip A. Serlin

Thank you, Irina, and good morning, everyone, and thank you for joining us on today’s call. As has been our practice, I will begin with a few prepared remarks before turning the call over to Mali Zeevi, our Chief Financial Officer, to briefly recap our financials. Afterwards, we will take your questions. Ella Sorani, our Chief Development Officer, is also available